Nothing Special   »   [go: up one dir, main page]

Bornstein et al., 1969 - Google Patents

Daunorubicine in acute myelogenous leukemia in adults

Bornstein et al., 1969

Document ID
8656167243439915186
Author
Bornstein R
Theologides A
Kennedy B
Publication year
Publication venue
Jama

External Links

Snippet

Daunorubicine (daunomycin, rubidomycin) is an antibiotic with antitumor activity in a wide variety of transplantable animal tumors. Its biologic mechanism of action is by inhibition of deoxyribonucleic acid synthesis with a lesser inhibition on ribonucleic acid synthesis. It is …
Continue reading at jamanetwork.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/30—Macromolecular compounds
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Bonadonna et al. Clinical evaluation of adriamycin, a new antitumour antibiotic
George et al. A study of “total therapy” of acute lymphocyticleukemia in children
Bonadonna et al. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127)
Barlow et al. Adriamycin and bleomycin, alone and in combination, in gynecologic cancers
Bradner et al. NEOCARZINOSTATIN (NSC-69856): AN ANTITUMOR ANTIBIOTIC EFFECTIVE AGAINST ASCITIC LEUKEMIA L1210 IN MICE¹, 2
Wittes et al. Combination chemotherapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck
Stewart et al. Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study
Carella et al. 4‐Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study
Bornstein et al. Daunorubicine in acute myelogenous leukemia in adults
JPS5998015A (en) Immunoactivator
Woodman et al. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943)
Cornu et al. Daunorubicin-DNA: Further clinical trials in acute non-lymphoblastic leukemia
Bonfante et al. Phase I study of 4-demethoxydaunorubicin
Cortes et al. Adriamycin in advanced bronchogenic carcinoma
Martoni et al. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer
Vogler et al. A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow
Schell et al. Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma
Vietti et al. Vincristine, prednisone, and daunomycin in acute leukemia of childhood. Writing committee
Cortes et al. Adriamycin (NSC-123127) in the Treatment of Acute Myelocytic Leukemia 1, 2, 3
Shaw et al. Adriamycin in combination chemotherapy of adult acute lymphoblastic leukemia: A Southwest Oncology Group Study
Moormeier et al. High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies
Lynch et al. Nitrogen mustard in the treatment of inoperable bronchiogenic carcinoma
DeWys et al. Synergistic antileukemic effect of theophylline and 1, 3-bis (2-chloroethyl)-1-nitrosourea
Teicher Combination of perfluorochemical emulsions and carbogen breathing with cancer chemotherapy
Burgess et al. Daunorubicin in the treatment of adult acute leukaemia